Pacer Advisors
APLS

Pacer Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Pacer Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,376
Closed -$52.8K – 2568
2024
Q2 		$52.8K Buy
1,376
+684
+99% +$31K ﹤0.01% 3128
2024
Q1 		$40.7K Buy
+692
New +$44.1K ﹤0.01% 3255
2021
Q2 		– Sell
-1,669
Closed -$72K – 1416
2021
Q1 		$72K Sell
1,669
-986
-37% -$46.7K ﹤0.01% 1359
2020
Q4 		$152K Sell
2,655
-736
-22% -$31.1K ﹤0.01% 1279
2020
Q3 		$102K Buy
+3,391
New +$101K ﹤0.01% 1246
2018
Q4 		– Sell
-2,602
Closed -$46K – 558
2018
Q3 		$46K Buy
+2,602
New +$48.1K ﹤0.01% 1147

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Pacer Advisors's APLS Position: Q3 2024 in Review

Pacer Advisors sold out of Apellis Pharmaceuticals (APLS) in Q3 2024, closing a stake of 1,376 shares — an estimated $52.8K sold.

Pacer Advisors first reported a position in APLS in Q3 2018 and held it in 6 quarters. The position peaked at $152K in Q4 2020. 265 funds tracked by Wall St. Rank hold APLS as of Q3 2024.

  • Pacer Advisors reported no remaining Apellis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 1,376 Apellis Pharmaceuticals shares in Q3 2024, an estimated $52.8K.
  • Pacer Advisors first reported a position in Apellis Pharmaceuticals in Q3 2018 and held it in 6 quarters.
  • Pacer Advisors's Apellis Pharmaceuticals position peaked at $152K in Q4 2020.
  • 265 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.